{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:18:11Z","timestamp":1787897891423,"version":"build-2784847793"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anti-amyloid monoclonal antibodies are approved as disease-modifying therapies for early Alzheimer\u2019s disease (AD), but real-world evidence remains limited, particularly among individuals treated during preclinical or minimally symptomatic stages. This study characterized clinical and biomarker trajectories among anti-amyloid therapy recipients across disease stages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We conducted a longitudinal retrospective case series of three biomarker-positive individuals from the Alzheimer\u2019s Disease Neuroimaging Initiative who received lecanemab or donanemab. Clinical, cognitive, cerebrospinal fluid, plasma biomarker, and amyloid PET data were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In all three cases, most of the observation period preceded anti-amyloid therapy initiation. Clinical trajectories varied by biomarker profile and treatment timing. Two participants received donanemab while cognitively normal or at an early transitional stage despite persistent amyloid- and tau-positive profiles. One participant received lecanemab after clinically significant impairment emerged. Cases 1 and 2 showed prolonged preservation of cognitive and functional performance despite sustained AD biomarker abnormalities and amyloid PET positivity. In case 2, age- and education-adjusted Wechsler Logical Memory testing detected progression to mild cognitive impairment despite preserved Mini-Mental State Examination and Clinical Dementia Rating scores. In contrast, case 3 showed persistent cognitive impairment and progression toward mild dementia. Conclusion: This case series illustrates substantial heterogeneity among real-world anti-amyloid therapy recipients. Persistent biomarker abnormalities may precede clinical decline for years, especially among highly educated individuals with substantial cognitive reserve. Conventional global screening tools may underestimate early decline and affect treatment eligibility decisions. Although not generalizable, these observations underscore the need for larger real-world studies characterizing clinical trajectories following anti-amyloid therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1900651","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:35:55Z","timestamp":1787895355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world anti-amyloid therapy beyond traditional symptomatic populations: a longitudinal case series"],"prefix":"10.3389","volume":"17","author":[{"given":"Jayoung","family":"Han","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Fairleigh Dickinson University College of Pharmacy and Health Sciences","place":["Florham Park, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Mathematics & Statistics, Old Dominion University College of Sciences","place":["Norfolk, VA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlingtina","family":"Esiaka","sequence":"additional","affiliation":[{"name":"Center for Health, Engagement and Transformation and Department of Behavioral Science, University of Kentucky College of Medicine","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufunmilola","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department Chair & Professor, U.S. Surgical Endowed Professor in Pharmacy Administration, Department of Pharmacy Practice & Science, University of Kentucky College of Pharmacy","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ALZ.13809","article-title":"2024 Alzheimer\u2019s disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimer\u2019s Dementia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ALZ.12362","article-title":"Population estimate of people with clinical Alzheimer\u2019s disease and mild cognitive impairment in the United States (2020\u20132060)","volume":"17","author":"Rajan","year":"2021","journal-title":"Alzheimer\u2019s Dementia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.14283\/JPAD.2021.23","article-title":"Diagnosis of early Alzheimer\u2019s disease: Clinical practice in 2021","volume":"8","author":"Porsteinsson","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2023.11704","article-title":"Donanemab for Alzheimer disease\u2014Who benefits and who is harmed","volume":"330","author":"Manly","year":"2023","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2310168","article-title":"Biomarker changes during 20 years preceding Alzheimer\u2019s disease","volume":"390","author":"Jia","year":"2024","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00756-4","article-title":"Characterizing the journey of early Alzheimer\u2019s disease in patients initiating lecanemab treatment in the United States: A real-world evidence study","volume":"14","author":"Sabbagh","year":"2025"},{"key":"B10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40266-025-01261-x","article-title":"Initial real-world evidence for lecanemab in the United States","volume":"43","author":"Brixner","year":"2026"},{"key":"B11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/S13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer\u2019s disease","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"B12","unstructured":""},{"key":"B13","doi-asserted-by":"publisher","first-page":"19024","DOI":"10.1038\/S41598-019-54204-Z","article-title":"Predicting clinical decline and conversion to Alzheimer\u2019s disease or dementia using novel Elecsys A\u03b2(1-42), pTau and tTau CSF immunoassays","volume":"9","author":"Blennow","year":"2019","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANEUROL.2024.3770","article-title":"Alzheimer disease as a clinical-biological construct\u2014An international working group recommendation","volume":"81","author":"Dubois","year":"2024","journal-title":"JAMA Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ALZ.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer\u2019s Dementia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1001\/JAMANEUROL.2025.0775","article-title":"IWG and AA criteria-Where the differences matter","volume":"82","author":"Kiselica","year":"2025","journal-title":"JAMA Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S1474-4422(12)70191-6","article-title":"Cognitive reserve in ageing and Alzheimer\u2019s disease","volume":"11","author":"Stern","year":"2012","journal-title":"Lancet Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/JCM12051759","article-title":"The protective role of cognitive reserve in mild cognitive impairment: A systematic review","volume":"12","author":"Corbo","year":"2023","journal-title":"J Clin Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/JAMANEUROL.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: Appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251331243","article-title":"Donanemab eligibility in early Alzheimer\u2019s disease: A real-world study","volume":"105","author":"Urso","year":"2025","journal-title":"J Alzheimer\u2019s Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100476","DOI":"10.1016\/j.tjpad.2025.100476","article-title":"Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic","volume":"13","author":"Rosenberg","year":"2026","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70662","article-title":"Donanemab in preclinical Alzheimer\u2019s disease: Screening and baseline data from TRAILBLAZER\u2010ALZ 3","volume":"21","author":"Yaari","year":"2025"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1900651\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:35:56Z","timestamp":1787895356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1900651\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":24,"alternative-id":["10.3389\/fpsyt.2026.1900651"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1900651","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1900651"}}